Blockade of β2-adrenoceptor, rather than β1-adrenoceptor, deteriorates cardiac anaphylaxis in isolated blood-perfused rat hearts by Kuda, Yuhichi et al.
Address for correspondence: Toshishige Shibamoto, MD, PhD, Department of Physiology II, Kanazawa Medical University, 
Uchinada Ishikawa 920-0293, Japan, tel: +81 76 218 8104, fax: +81 76 286 8010, e-mail: shibamo@kanazawa-med.ac.jp
Received: 14.12.2016 Accepted: 24.02.2017
Blockade of b2-adrenoceptor, rather than  
b1-adrenoceptor, deteriorates cardiac anaphylaxis 
in isolated blood-perfused rat hearts
Yuhichi Kuda1, Toshishige Shibamoto1, Wei Yang1, 2, Tao Zhang1, 3,  
Mamoru Tanida1, Yasutaka Kurata1
1Department of Physiology II, Kanazawa Medical University, Uchinada, Japan 
2Department of Infectious Disease, Shengjing Hospital of  
China Medical University, Shenyang, China 
3Department of Colorectal and Hernia Surgery, The Fourth Affiliated Hospital  
of China Medical University, Shenyang, China
Background: Cardiac anaphylaxis is one of the features of anaphylactic hypotension. Patients treated 
with propranolol, a nonselective b-adrenoceptor (AR) antagonist, develop severe anaphylaxis, but the 
mechanism remains unknown. Under examination were the effects of b1- and b2-AR antagonist on 
anaphylaxis-induced coronary vasoconstriction and cardiac dysfunction in isolated blood-perfused rat 
hearts. 
Methods: Isolated hearts from ovalbumin-sensitized Wistar rats were subjected to coronary perfusion 
with blood at a constant pressure and measurements were made of coronary blood flow and left ventricu-
lar (LV) pressure. Following pretreatment with selective b2-AR antagonist ICI118,551 or selective b1-AR 
antagonist atenolol, cardiac anaphylaxis was induced by intracoronary injections of ovalbumin antigen. 
LV contractility was evaluated by the maximum increasing rate of systolic LV pressure (dP/dtmax). 
Results: In response to antigen administrations, ICI118,551 pretreated hearts showed a greater de-
crease in coronary blood flow and consequently a greater increase in coronary vascular resistance than 
the atenolol pretreated hearts. Pretreatment with ICI118,551 caused a greater decrease in dP/dtmax than 
those with atenolol. 
Conclusions: Cardiac anaphylaxis-induced contractile dysfunction and coronary spasm are severe in b2-,  
rather than b1-AR antagonist, pretreated isolated blood-perfused rat hearts. (Cardiol J 2017; 24, 4: 403–408)
Key words: cardiac anaphylaxis, isolated perfused rat heart, β-adrenoceptor antagonist, 
cardiac contractility
Introduction
Anaphylactic shock is sometimes life-threat-
ening and accompanied by cardiac manifestation, 
which is clinically characterized by acute myocar-
dial ischemia via coronary artery spasm and con-
tractile dysfunction of left ventricle (LV) [1–5] and 
is called “Kounis syndrome” [6]. Experimental 
models of cardiac anaphylaxis were established in 
excised sensitized rat hearts perfused with crys-
talloids [7, 8], in which coronary vasoconstriction 
and cardiac dysfunction, evidenced by a decrease 
403www.cardiologyjournal.org
BASIC SCIENCE AND EXPERIMENTAL CARDIOLOGY
Cardiology Journal 
2017, Vol. 24, No. 4, 403–408
DOI: 10.5603/CJ.a2017.0034 
Copyright © 2017 Via Medica
ISSN 1897–5593ORIGINAL ARTICLE
in the maximum increasing rate of LV pressure 
(dP/dtmax), were induced by administration of the 
antigen ovalbumin into the coronary artery. Fur-
thermore, new cardiac anaphylaxis models have 
recently been developed using the cross-circulated 
blood-perfusion method which permits analysis 
of LV mechanical works in excised whole heart 
preparations under more physiological conditions 
than crystalloid perfusion [9].
Patients with pre-existing cardiovascular 
diseases and those treated with propranolol, 
a b-adrenoceptor (AR) antagonist, have increased 
severity of anaphylaxis [10, 11]. Propranolol is 
a nonselective b-AR antagonist and can block 
both b1-AR and b2-AR. It has recently been dem-
onstrated that the blockade of b-AR augments the 
severity of anaphylactic hypotension in anesthe-
tized rats, and that blockade of b2-AR rather than 
b1-AR exerts primarily the detrimental action on 
systemic anaphylaxis via enhancing the pulmonary 
vasoconstriction and bronchoconstriction [12]. 
Therefore, cardiac anaphylactic reactions may also 
be augmented by blockade of b-AR. If so, it should 
be clarified whether blockade of b1-AR or b2-AR 
exerts a deleterious effect on cardiac anaphylaxis.
The purpose of this study was to determine the 
effects of b1-AR and b2-AR antagonists on coronary 
vasoconstriction and cardiac dysfunction during 
cardiac anaphylaxis in isolated blood-perfused rat 
hearts [9].
Methods
Animals
Male Wistar rats (n = 14) weighing 374 ± 
± 27 g were assigned to one of the two groups: 
1) the selective b2-AR antagonist ICI118,551 
(3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]
butan-2-ol) group; and 2) the selective b1-AR 
antagonist atenolol group. Rats were housed in 
a cage (28 cm × 21 cm × 45 cm; 3 rats/cage) and 
maintained at 23°C and the humidity of 55% ± 
± 15% under pathogen-free conditions on a 12:12-h 
dark-light cycle, and allowed food (CE-2, CLEA 
Japan, Tokyo, Japan) and water ad libitum. The 
experiments conducted in the present study were 
approved by the Animal Research Committee of 
Kanazawa Medical University. 
Antigen sensitization
Rats were actively sensitized by the subcu-
taneous injection of an emulsion made by mixing 
equal volumes of complete Freund’s adjuvant 
(0.5 mL) with 1 mg ovalbumin (grade V; Sigma 
Chemical Company, St. Louis, MO, USA), as de-
scribed previously [13].
Isolated cross-circulated  
rat heart preparation
Two weeks after the sensitization, hearts were 
excised and coronary perfused with blood of meta-
bolic supporter and blood supplier rats at a constant 
pressure by the cross-circulation method [9]. 
A thin latex balloon inserted into excised heart LV 
was connected to a pressure transducer (Life Kit 
DX-312, Nihon Kohden, Tokyo, Japan) to measure 
LV pressure during isometric contractions, with 
a maximum systolic LV pressure adjusted to 
120–140 mm Hg. The heart rate was maintained at 
300 bpm by electrical pacing to eliminate chrono-
tropic influences. The systemic arterial pressure 
of a supporter rat served as the coronary perfusion 
pressure of 107 ± 15 (SD) mm Hg. Arterial pH, 
PO2, and PCO2 of the supporter rat were maintained 
within their physiological ranges (pH = 7.3–7.4; 
PO2 = 95–100 mm Hg; PCO2 = 35–40 mm Hg) 
with supplemental oxygen and sodium bicarbonate.
Measurement items
LV pressure, coronary arterial pressure, and 
coronary venous pressure were continuously 
measured with the pressure transducer (Life Kit 
DX-312, Nihon Kohden) and digitally recorded by 
PowerLab (AD Instruments, Castle Hill, Australia), 
which could determine the time derivative of LV 
pressure and dP/dtmax as an index of LV contractility 
in real time. Total coronary blood flow (mL/min/g) 
was continuously measured with an electromagnet-
ic flow meter (MFV-3100, Nihon Kohden) placed in 
the middle of the coronary venous drainage tubing 
from the superior vena cava. For assessing coro-
nary circulation, the coronary vascular resistance 
was determined by the following equation:
Coronary vascular resistance = (Coronary 
arterial pressure – Coronary venous pressure) / 
/ Coronary blood flow [mm Hg × min × g/mL].
Experimental protocol
Baseline measurements of LV pressure, coro-
nary arterial pressure, coronary venous pressure 
and coronary blood flow (with determinations 
of dP/dtmax and coronary vascular resistance) 
were first performed at 10 min after pretreat-
ment with atenolol (0.25 mg) or ICI118,551 
(0.06 mg) injected into the coronary artery. The 
administered doses of atenolol and ICI118,551 
were one third of the total doses intravenously 
injected into the whole body of in vivo rats [12], 
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Results
Figure 1 shows representative records of LV 
pressure, coronary arterial pressure, coronary 
venous pressure, coronary blood flow, dP/dtmax 
and coronary vascular resistance for 10 min after 
an antigen challenge from a rat heart pretreated 
with atenolol (Fig. 1A) and ICI118,551 (Fig. 1B). 
Averaged values of the measured variables are 
shown at an interval of 30 s in Figures 2 and 3. 
In the atenolol pretreated hearts, coronary blood 
flow (4.4 ± 0.3 mL/min/g at the baseline) began 
to decrease as early as 1.5 min after antigen 
challenge and progressively decreased to the 
nadir of 1.7 ± 0.3 mL/min/g at 2.5 min, and then 
gradually returned toward the baseline level during 
10 min measurements (Fig. 2A). Coronary ve-
nous pressure slightly but significantly decreased 
by ~2 mm Hg at 1.5–6.5 min, whereas coro-
nary arterial pressure did not change throughout 
10 min recordings (data not shown). The calcu-
lated coronary vascular resistance showed signifi-
cant increases from the baseline value of 25 ± 3 
mm Hg•min•g/mL to the peak of 72 ± 9 mm Hg • 
min • g/mL, i.e., 2.9-fold the baseline level, at 
2.5 min, followed by subsequent partial recovery 
toward baseline level (Fig. 2B). In ICI118,551 
pretreated hearts, following antigen injection, 
coronary blood flow decreased from the baseline of 
4.0 ± 0.2 mL/min/g to the nadir of 0.9 ± 0.2 mL/ 
/min/g at 2.5 min, which was significantly smaller 
than that in atenolol pretreated hearts (Fig. 2A). 
the doses were enough for coronary circulation 
alone. Following the baseline measurements, the 
antigen (ovalbumin 1.2 mg) dissolved in 300 μL 
saline was administered into the coronary artery, 
which yielded the forcible constriction of the left 
coronary artery (main trunk). Direct injection of 
the antigen ovalbumin into coronary arteries of 
isolated sensitized rat hearts is a well-established 
experimental method to create rat cardiac ana-
phylaxis models efficiently [7, 8]. The variables 
were continuously measured for 10 min after 
the antigen administration. We determined the 
temporal changes in coronary blood flow and LV 
contractility during cardiac anaphylaxis.
Drugs
All drugs were purchased from Sigma Chemical 
Company (St. Louis, MO, USA). All drugs were dis-
solved in saline. The doses of the antagonists were 
determined according to the previous study [12].
Statistical analysis
All results are expressed as the means 
± standard error of the mean (SEM). Multiple 
intra-group comparisons were performed using the 
repeated-measures analysis of variance, followed 
by the Bonferroni post hoc analysis. Comparisons 
between the atenolol and ICI118,551 groups were 
performed by Student t-test. The p value of < 0.05 
was considered statistically significant. All statis-
tical analyses were performed by StatView (SAS 
Institute Inc., Cary, NC, USA).
Figure 1. Representative recordings of left ventricular pressure, coronary arterial pressure, coronary venous pressure, 
coronary blood flow, maximum increasing rate of systolic left ventricular pressure (dP/dtmax) and coronary vascular 
resistance in the atenolol (A) and ICI118,551 (B) groups.
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Consequently coronary vascular resistance in 
ICI118,551 hearts increased 6.2-fold from the 
baseline at 2.5 min, which was also significantly 
greater than the 2.9-fold increase in atenolol hearts 
(Fig. 2B).
In atenolol pretreated hearts, in parallel with 
the coronary blood flow reduction, the systolic LV 
pressure (127 ± 2 mm Hg at the baseline) and dP/ 
/dtmax (2954 ± 166 mm Hg/s at the baseline) began 
to decrease at 1.5 min after antigen administra-
tion, decreased to the nadir of 61 ± 4 mm Hg and 
1743 ± 58 mm Hg/s (i.e., to 48% and 59% of the 
baseline levels), respectively, at 2.5 min, and then 
gradually went back to the baseline level (Fig. 3). In 
ICI118,551 pretreated hearts, LV pressure (135 ± 
± 4 mm Hg at the baseline) and dP/dtmax (3422 ± 
± 157 mm Hg/s at the baseline) decreased to the 
nadir of 39 ± 3 mm Hg and 1250 ± 179 mm Hg/s 
(i.e., to 29% and 37% of baseline levels) respec-
tively, which were significantly smaller than those 
in the atenolol pretreated hearts (Fig. 3).
Discussion
In the present study, it was found that pretreat-
ment with the selective b2-AR blocker ICI118,551 
reduced the cardiac contractility index of dP/dtmax 
more dramatically than with the selective b1-AR 
blocker atenolol in isolated blood-perfused sen-
sitized rat hearts injected with the antigen. This 
demonstrates that the blockade of b2-AR exerted 
more detrimental effects on anaphylaxis-induced 
cardiac dysfunction than that of b1-AR.
In the present study the response of the non-
-pretreatment sensitized heart (the anaphylaxis 
group) or non-sensitized heart (the control group) 
Figure 2. Time course data of coronary blood flow (A) and coronary vascular resistance (B) after an injection of the 
ovalbumin antigen. Circle, the atenolol group (n = 7); triangle, the ICI118,551 group (n = 7). Values are means ± SEM; 
*p < 0.0002 vs. baseline (by the Bonferroni post hoc test); #p < 0.05 vs. the atenolol group (by Student t-test); 
SEM — standard error of the mean.
Figure 3. Time course data of maximum increasing 
rate of systolic left ventricular pressure (dP/dtmax) after 
an injection of ovalbumin antigen. Circle, the atenolol 
group (n = 7); triangle, the ICI118,551 group (n = 7). 
Values are means ± SEM; *p < 0.0002 vs. baseline (by 
the Bonferroni post hoc test); #p < 0.05 vs. atenolol 
group (by the Student t-test); SEM — standard error of 
the mean.
406 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 4
to the antigen was not examined because they had 
already been reported in a previous article [9]. Us-
ing the previously reported data, herein provided 
(Fig. 4) shows all four groups data of coronary 
vascular resistance, coronary blood flow and dP/ 
/dtmax at baseline and 2.5 min after antigen injec-
tion when the peak changes of the variables were 
observed. It should be noted that the magnitudes 
of increased coronary vascular resistance, reduced 
coronary blood flow and reduced dP/dtmax in the at-
enolol pretreated hearts of the present study were 
comparable to those of the non-pretreated hearts 
of the previous study, and were significantly differ-
ent from those of the ICI118,551-pretreated heart 
and the non-sensitized heart [9]. This evidence 
indicates that b2-AR antagonist, but not b1-AR 
antagonist, aggravates cardiac anaphylaxis.
As previously demonstrated, b2-AR an-
tagonist ICI118,551, rather than b1-AR antago-
nist atenolol, exerts a deleterious effect on 
rat anaphylactic shock [14]. The mechanism, 
however, remains unclear. The present results 
demonstrate that b2-AR antagonist causes more 
severe antigen-induced cardiac dysfunction than 
b1-AR antagonist, which may account, at least 
in part, for the detrimental action of the b2-AR 
antagonist on anaphylactic hypotension. Another 
possibility is that b2-AR antagonist increased 
vascular permeability, resulting in a reduction 
of effective circulating blood volume and then 
anaphylactic hypotension, since it has been 
shown that b-AR-mediated signaling contrib-
utes to endothelial barrier maintenance under 
baseline conditions [15, 16]. In addition, b2-AR 
antagonists might exert deleterious effects on 
the antigen-induced pulmonary vasoconstriction 
and bronchoconstriction, as observed in b2-AR 
antagonist-pretreated rats [12]. 
The mechanism for b2-AR antagonist-induced 
deterioration of cardiac contractility during ana-
phylaxis may be related to the exaggerated coro-
nary vasoconstriction, which causes ischemia of 
LV, and finally cardiac dysfunction. It was dem-
onstrated that anaphylactic cardiac dysfunction 
is almost exclusively due to coronary vasocon-
striction in the isolated blood-perfused rat hearts 
[9]: during cardiac anaphylaxis LV contractility 
transiently decreased in parallel with coronary 
blood flow, and the forcible coronary blood flow 
reduction mimicking the temporal changes in 
coronary blood flow during anaphylaxis caused 
a reduction in LV contractility similar to that dur-
ing anaphylaxis. On the other hand, activation of 
b2-AR in the heart causes coronary vasodilatation 
[17]. Furthermore, Watson et al. [18] have re-
cently reported that the b2-AR agonist formoterol 
increases coronary blood flow and LV contractility 
most likely via b2-AR-mediated coronary vasodila-
tion in isolated perfused rat hearts. Elimination 
Figure 4. Time data of coronary vascular resistance, 
coronary blood flow and maximum increasing rate of 
systolic left ventricular pressure (dP/dtmax) at baseline 
and 2.5 min after an injection of the ovalbumin anti-
gen in non-sensitized group (Control; n = 7), sensitized 
non-pretreatment group (Anaphylaxis; n = 7), atenolol 
group (n = 7) and ICI118,551 group (n = 7). Values are 
mean ± SEM; *p < 0.05 vs. baseline (by the Student 
t-test); #p < 0.05 vs. the Anaphylaxis group (by the 
Fisher’s post hoc test); SEM — standard error of the 
mean.
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of this beneficial action of b2-AR may lead to ag-
gravation of anaphylactic cardiac dysfunction in 
the present study. 
Limitations of the study
There are limitations of the present study. This 
study examined the acute effects of b-AR antagonists. 
However, patients usually take chronically b-AR 
antagonists; all the adaptive mechanisms, such as 
desensitization, that are likely to occur were not 
captured by the present study design. Furthermore 
the patients with b-AR antagonists may not have 
a healthy intact heart, as was examined in the present 
study, but a coronary sclerotic or failing heart. Thus, 
care should be taken when extrapolating the present 
findings to clinical situations. Further study may be 
required using animals with chronic administration 
of b-AR antagonists or with diseased hearts.
Conclusions
In summary, we determined the pretreatment 
effects of b1-AR and b2-AR antagonists on cardiac 
contractility, dP/dtmax, in isolated blood-perfused rat 
hearts suffering from anaphylaxis. It was concluded 
that the blockade of b2-AR causes greater coronary 
vasoconstriction, and consequently severer cardiac 
dysfunction than that of b1-AR. 
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